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Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematologic malignancies characterized by peripheral cytopenias, a hypercellular marrow with ineffective hematopoiesis, and a propensity to progress to acute myeloid leukemia (AML) 1, 2 . MDS is thought to arise from a primitive hematopoietic progenitor that has acquired genetic and/or epigenetic abnormalities 3 . The cell of origin in MDS is thought to reside within the CD34 + population, based on multiparameter flow cytometry and fluorescence in situ hybridization studies, global gene expression analysis, as well as on xenotransplantation of marrow cells from MDS patients into immunodeficient mice [4] [5] [6] [7] . However, in comparison with other hematologic malignancies there is limited biological understanding of the molecular abnormalities that contribute to the pathogenesis of MDS.
The current categorization of MDS according to The World Heath Organization (WHO)
consists of eight subtypes, based on biological, genetic, and morphological features 8, 9 . In addition, an International Prognostic Scoring System (IPSS) -that takes into account the proportion of leukemic blast cells in the marrow, the number of cytopenias, and the karyotypehas been devised to assign patients to risk categories with respect to survival and the likelihood of AML transformation 2 . The importance of cytogenetics in risk stratification has been verified in several studies, but this is of limited value in patients with lower-risk subtypes because approximately 50% of these patients do not have karyotypic abnormalities that are detectable using standard techniques [1] [2] [3] . Greater than 50% of individuals diagnosed with MDS are of the lower-risk groups, which generally correspond to the morphologic subtypes of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS), MDS with (del)5q 2, 8 .
To further our biological understanding, particularly of low-risk subtypes of MDS, we performed a high-resolution whole genome array comparative genomic hybridization (aCGH)
analysis of CD34 + progenitor cells isolated from the marrow of MDS patients. Of note, the aCGH analyses in this study were all conducted on unamplified genomic DNA from the CD34 + fraction, thus eliminating biases secondary to PCR amplification. We also evaluated the effectiveness of high-resolution analysis of the structural integrity of the genome on providing additional prognostic information in patients with lower-risk MDS. Our whole genome aCGH analysis of CD34 + cells isolated from the marrow of a mixed group of karyotypically normal (n = 25) and abnormal (n = 15) MDS patients revealed that extensive genome alteration involving > 3
Mb detectable by aCGH correlated with poorer overall survival, and was more frequently associated with transformation to AML.
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Study Design Sample Collection
Bone marrow samples were obtained from 44 patients diagnosed with MDS, of which 38 were collected at the time of diagnosis. Of these, 40 patients with IPSS score ≤ 1.0 (Tables 1S and 2S; median age 76 years, range: 33-90; and mean age of 71.3 ± 1.9 years) were included in the survival analysis. Seven of the 44 patients received treatment during the course of the disease (3 received allogeneic bone marrow transplants, 2 received trials of erythropoietin, 1 received hydroxyurea, and 1 received anti-thymocyte globulin). Blood samples were obtained from 15 elderly subjects without evidence of marrow-derived malignancy following informed consent according to the Declaration of Helsinki. Ten were healthy subjects with no evidence of cancer (other than non-melanoma skin cancer in two) whose blood was collected as part of a healthy aging study. Five patients had marrow collected as part of the staging procedure for nonHodgkin lymphoma, but did not exhibit marrow or peripheral blood involvement by lymphoma.
All protocols were approved by the Clinical Research Ethics Board of the British Columbia
Cancer Agency/University of British Columbia. An MDS-derived CD34 + multipotent cell line (MDS-L) was used as an additional control 10, 11 . AllPrep DNA/RNA Mini Kit (Qiagen). Normal reference DNA was purchased as a pool of either male or female genomic DNA (Novagen).
Cell isolation

Whole genome tiling-path aCGH analysis
Details of whole genome array construction and probe prime labeling and hybridization have been described previously 12, 13 . The submegabase-resolution tiling set (SMRT) array contains 32,433 overlapping BAC-derived DNA segments that provide tiling coverage over the entire human genome with a theoretical resolution of 50 kb 12, 14 . All clones were spotted in duplicate.
Sample (MDS) and reference (normal diploid) genomic DNA (50-200 ng each) were separately labeled using Cyanine 3 and Cyanine 5 dCTPs fluorescence markers, respectively. The images were captured with a charge-coupled device camera, and analyzed using an ArrayWorx scanner and SoftWorx Tracker Spot Analysis software (Applied Precision). SeeGH custom software (available by request to SeeGH@bccrc.ca) was used to visualize all data as log ratio plots 12, 15 .
Clones with standard deviation between duplicate spots of > 0.1 were filtered from the raw data.
In order to avoid false-positives due to hybridization noise, a minimum of two overlapping consecutive clones showing change was required for a region to be considered altered.
Breakpoints of genomic alterations were identified using a hidden Markov model algorithm, and verified by visual inspection, as described 16 17 .
Fluorescent in situ hybridization (FISH)
For FISH analysis, interphase chromosomes were prepared from the MDS-L cell line, and as a control, 3 normal BM samples to determine technical and biological variation at these loci. For detection of gene amplification at chromosome band 17q12, BAC probes within the region of interest (RP11-072I20) and one outside the region of interest (RP11-686E5) were used. DNA from the BAC clones was isolated and labeled with either Spectrum Orange-dUTP or Spectrum
Green-dUTP by nick translation (Abbott Molecular Inc.). Interphase FISH using a modified formamide free protocol (Abbott Molecular Inc.) was followed. Image capture was performed with Ziess Axioplan II microscope equipped with the appropriate filters for DAPI, Spectrum
Oranage, and Spectrum Green, and the Metasystem ISIS imaging software. At least 100 interphase nuclei were analyzed. A locus was considered to be amplified when more than 2 FISH signals were present.
Statistical Analysis
Spearman correlation was used to assess the relationship between age and total genomic alteration (TGA). Differences in TGA between normal controls and MDS patients were assessed using the Mann-Whitney test. Overall and AML-free survival was calculated by the KaplanMeier method and differences between groups were determined by the log-rank test. AML-free survival was analyzed by censoring individuals who died without progressing to AML. Analysis was carried out using GraphPad Prism4 (GraphPad Software, San Diego, CA) or JMP (JMP Software, Carey, NC). Figure 1A) . Results of the cytogenetic analysis are summarized in Tables 1 and 2S .
Results
Twenty-five patients in this cohort had no karyotypic aberration. In contrast, only 8 of 44
patients had no detectable copy number alterations by aCGH ( Figure 1A ). Of the 16 patients with abnormal metaphase cytogenetic profiles, 11 were confirmed by aCGH to have the identical copy number alteration. In two cases (patients 5 and 25), the karyotype identified 2 independent clones. In both cases the minor clone population was below the threshold of detection by aCGH (<30%). The cytogenetic findings for patient 20, represent genomic alterations that do not involve a copy number change and would not be detectable by aCGH. For patients 11 and 22, deletion of the Y chromosome was not detectable by aCGH.
The total number of genomic copy number alterations detected by aCGH in 44 MDS samples was 135 (3.1 alterations per patient, ranging from 0-12 changes) ( Figure 1B ; Table 1 ).
The median size of copy number alterations was 0.7 Mb with a mean of 10.5 Mb. In contrast, we detected copy number alterations in CD34 + cells from 15 non-diseased ("Normal") controls with a median size of 0.4 Mb and mean 0.5 Mb all of which have been identified as common CNVs (Table 4S ). Most genomic amplifications displayed log 2 ratios (~0.4) indicative of low copy number gains (i.e. duplications), which ranged in size from 0.1-143.9 Mb (Table 1; Figure 1B ).
In most cases deletions represented loss of a single copy, and these deletions ranged in size from 0.2 -158.1 Mb. Overall, we identified more than 85 distinct amplifications and deletions in CD34 + cells from 44 low-risk MDS patients by aCGH, of which 66 have not been previously described to our knowledge (Table 2) . Twenty-one alterations involved recurring gains (n = 9) or deletions (n = 12) (Table 3S ). Of the 25 MDS patients with normal cytogenetic studies, 20
exhibited at least one disease-associated copy number alteration ( Table 1) .
Identification of genetic changes in peripheral blood using array CGH
To determine whether copy number changes identified were detectable in the peripheral blood, aCGH was performed on mononuclear cells obtained at the time of the diagnostic marrow specimen from select MDS patients. We detected copy number alterations in the circulating mononuclear cell population that had been identified in CD34 + cells, that were absent in matched CD3 + cells, in both cases examined. For patient 1, the amplification at chromosome band 11q24.2-qter detected in the CD34 + marrow cells was also found in the circulating mononuclear cells ( Figure 1S ). Similarly, deletion of chromosome 7 in patient 22 was also detected in the peripheral blood mononuclear cells ( Figure 1S ). These findings demonstrate that genomic changes are readily detectable in the peripheral blood, and that aCGH of circulating nucleated cells may be a viable alternative to conventional cytogenetics in the diagnostic workup of MDS.
Amplification of the hominoid oncoprotein TBC1D3 is a novel and recurring genomic alteration in MDS
We identified a 0. Figure 2C , FISH analysis confirmed an increase in copy number (~20% of cells had >3 copies per cell) at band 17q12, which was not detectable on 3 BM samples from healthy donors.
To determine whether the duplication at 17q12 results in increased mRNA levels of TBC1D3, we performed quantitative RT-PCR on total RNA from MDS marrows exhibiting amplification at band 17q12 (n = 4), MDS marrows with diploid band 17q12 (n = 9), and normal controls (n = 6). MDS marrows with amplification at band 17q12 had increased mRNA expression of TBC1D3 as compared to MDS patients or normal controls without the 17q12 amplification ( Figure 2B ).
Since the TBC1D3 locus lies within a region that is listed as a CNV (Variation_7155; frequency = 0.02), we determined whether the amplification at band 17q12 was a somatic or germline mutation by performing aCGH on matched CD3 + T cells from the marrow of 3 patients from whom additional material was available. While it is generally felt that MDS arises in a pluripotent stem progenitor cell, there is some debate as to whether the T cell population is involved in this disorder 27 . As shown in Figure 2D , the amplification at band 17q12 was absent in the CD3 + cells of two patients (patients 3 and 14), and clearly detectable in another (patient 33). Known high-frequency CNVs present in the CD34 + fractions at chromosome 5q (patients 14 and 33) and chromosome 19p (patient 3) were clearly detectable in the CD3 + cell populations, and served as internal controls for the CD3 + aCGH analysis in each case ( Figure 2D ). These findings suggest that at least in 2 cases (patients 3 and 14), the amplification at band 17q12 is not present as a constitutional variation.
Additional findings of interest include 3 patients (17, 33, and 40) with a deletion encompassing the erythropoietin receptor EPOR (band 19p31.2) ( Figure 2E ). Reduced levels of EPOR has been reported in some MDS patients 28, 29 . To determine whether this deletion correlated with functional responses to erythropoietin, we examined hematopoietic progenitor assays performed under defined conditions (including exogenous erythropoietin) at the time of diagnosis in these patients. Loss of the region encompassing EPOR correlated with reduced colony formation of CFU-E, but not BFU-E, as compared to MDS patients with a diploid EPOR locus (Fig. 2F ). These findings are consistent with the critical role of EPOR signaling in the proliferation and/or survival of relatively late erythroid progenitors (CFU-E), but not for early erythroid progenitors (BFU-E) as demonstrated in gene-targeted mice 30 , and may explain the erythropoietin-resistance seen in some patients with MDS. (Table 3) . Most strikingly, patient 17 had 1 change detected in the CD34 + cell population, and an additional 13 unique alterations in the CD34 -cell fraction, suggesting expansion of a specific clone favoring differentiation and/or proliferation or survival.
Comparison of CD34
Total genomic alteration (TGA) in CD34 + cells increases with age
A related theory of the pathogenesis of MDS holds that the accumulation of genomic changes secondary to exposure to genotoxic damage over time gives rise to the abnormal hematopoietic stem cell clone 1 . Indeed, increased age is a poor prognostic indicator in MDS 32 .
We thus examined whether the total genomic alteration (TGA), as measured by the sum of the sizes of amplifications and deletions, correlated with age. As demonstrated in Figure 3A Mb, range 0.6 to 35.8 Mb; P = 0.0003) ( Figure 3B ). These findings suggest that the loss of genomic integrity seen in CD34 + cells from MDS patients was related to their disease, rather than their increased age.
Total genomic alteration (TGA) predicts overall and leukemia-free survival
Cytogenetic findings are an established prognostic factor in MDS [33] [34] [35] . However, although several recurrent genetic alterations were identified by aCGH (Table 3S) , the relatively small size of this cohort precluded assessment of prognosis based on specific genetic changes. We therefore asked whether TGA identified by aCGH could assign a prognostic category to patients with lower-risk MDS. The median duration of follow-up from time of diagnosis of the surviving study cohort was 54.5 months (range, 22-188 months). Because none of the age-matched controls had a TGA greater than 2.6 Mb, MDS patients were stratified into 2 groups based on whether the TGA in the CD34 + cells was ≤ 3 Mb (n = 17) or > 3 Mb (n = 23). Comparison of the two groups revealed a median overall survival of 33 months for the group showing a TGA > 3
Mb, whereas median overall survival was not reached in the group with a TGA ≤ 3 Mb (P = 0.0017; Figure 4A ). Similarly, AML-free survival was prolonged in the good-risk category (P = Figure 4B ). In contrast and as expected, differentiation by the IPSS score into Low-risk (IPSS = 0) and the Int-1 groups (IPSS = 0.5 or 1.0) was not adequate to separate the two groups with respect to overall survival (P = 0.12; Figure 4C ), or AML-free survival (P = 0.33; Figure   4D ). When assessing only patients with a normal karyotype, the TGA cutoff of 3 Mb was still able to separate patients into a low-risk group (median survival not reached), and a higher-risk group (median survival 39 months, P = 0.0021; Figure 4E ). Again, in this lower-risk group the IPSS score was not able to substratify patients into prognostic groups (P = 0.54; Figure 4F ).
Analysis of only the patients whose diagnostic marrows were assessed by aCGH and who received only supportive treatment (n = 30) revealed that a TGA of 3 Mb still predicts overall survival (P = 0.0003) and AML-free survival (P = 0.024) ( Figure 2S ).
Discussion
The low-risk subtypes of MDS represent approximately 50% of all MDS patients. At least 50% of the low-risk MDS patients have a normal karyotype by conventional cytogenetics 2, 8 .
To expand our understanding of lower-risk subtypes of MDS, and identify MDS-initiating alterations we performed submegabase BAC whole genome aCGH analysis of CD34 + cells of the marrow of 44 lower-risk MDS patients. Our findings revealed cryptic structural DNA alterations that were not detectable by standard cytogenetic analysis. Due to the heterogeneous nature of the marrow from MDS patients, acquisition of additional genetic abnormalities during malignant clone evolution, and the high propensity to undergo apoptosis, assaying the CD34 + cell population is more likely to reveal genomic alterations that correspond to initiation of the disease. Although most patients tested had normal karyotype, our analysis identified 22 novel recurring copy number alterations by aCGH.
We also evaluated the effectiveness of high-resolution aCGH analysis in providing prognostic information for patients with lower-risk MDS. Our analysis of a mixed group of karyotypically normal (n = 25) and abnormal (n = 15) MDS patients revealed that minimal genomic alteration corresponding to < 3 Mb detectable by aCGH correlated with significantly increased overall survival, and was less frequently associated with transformation to AML, as compared to IPSS stratification alone. Recently, it has been suggested that a pre-MDS phase, labeled Idiopathic Cytopenia of Undetermined Significance (ICUS), may exist 36 . It is possible that patients who do not meet the current criteria for MDS, but still have unexplained cytopenias, may fit into the group exhibiting minimal genomic alteration of CD34 + cells. However, further work will be needed to delineate these subgroups based on high-resolution aCGH.
Several groups have performed conventional and aCGH to identify genomic alteration in marrow cells from patients with MDS [37] [38] [39] [40] [41] [42] [43] . In general, these studies utilized total marrow cells as the source of DNA and did not focus on the low-risk MDS subtypes. Nevertheless, single nucleotide polymorphism (SNP) genotyping by two independent groups revealed some copy number alterations in accordance with our findings [43] [44] [45] (Table 2 Our data suggest that high-resolution aCGH will be a useful diagnostic and prognostic tool in the evaluation of patients with MDS falling into the low-risk group, and that more extensive genome alterations will be a feature of older patients. In agreement with our findings, Mohamedali and colleagues have shown that the presence of copy number changes in amplified DNA from CD34 + cells by SNP genotyping provides prognostic significance in MDS patients 44 .
Use of SNP genotyping on the total population of marrow cells from MDS patients of all risk groups did not substratify patients into prognostic groups 46 . However, when only patients in the IPSS Int-1 subgroup were evaluated, additional SNP array copy number changes to those found by conventional cytogenetic analysis was predictive of poorer overall survival 46 . Our findings suggest that measurement of total genomic alteration at high-resolution by aCGH provides prognostic information in lower-risk MDS patients (IPSS score ≤ 1) irrespective of conventional cytogenetic findings. Nevertheless, these aforementioned examples and our findings confirm that high-resolution genotyping improves prognostication in low-risk MDS patients independent of aCGH platform.
In our analysis we did not take into consideration the favorable prognosis afforded by specific cytogenetic alterations, such as deletion of the long arm of chromosome 5 2 . It is possible that substratification based on cytogenetic changes known to have prognostic implications could further improve the predictive capabilities of aCGH. Credence for this hypothesis is best exemplified by our aCGH finding on patient 1. This patient was originally diagnosed with 5q-syndrome, which has a favorable prognosis, yet succumbed rapidly after the initial diagnosis.
However, our aCGH findings of additional copy number alterations in this patient are in accordance with the less favorable prognosis of del(5q) in the presence of additional alterations.
Thus, consideration should be given to incorporating aCGH findings into a prognostic scoring system for MDS, which could be achieved by replicating this study in a larger multicentre prospective trial.
There is minimal understanding of the specific molecular pathways that are involved in (Figure 2 ). TBC1D3D (also called PRC17) was originally identified as a gene that was amplified in 15% of primary and 53% of metastatic prostate cancers 47 .
Furthermore, overexpression of TBC1D3D promoted anchorage-independent growth of NIH3T3 cells and tumor formation in nude mice 47 . An extended analysis of a recurring duplication at band 17q12 by comparing CD34 + and CD3 + cell populations by aCGH revealed that in 2 of 3 patients the duplication was only present within the CD34 + cells. Interestingly, deletion of the TBC1D3 locus was noted in one normal subject (Table 4S) .
Some of the copy number alterations detected in CD34 + cells, but not in matched CD3
+ cells, overlap with previously described regions known to harbor CNV. These non-random segments of genomic DNA demonstrate variation in copy number, and this variation from individual to individual, or even within cell populations of an individual, may have important functional consequences 48 . As is the case with single nucleotide polymorphisms, some CNV include potential oncogenes or tumor suppressor genes that have been implicated in other cancers, such as alterations at chromosome band 17q12 (TBC1D3) 47 and band 5q13.1-q13.2 (RAD17) 49 (Table 3S) . In both instances, the copy number change was not present in the CD3 + cells suggesting a clonal copy number alteration in the CD34 + population. It has also recently been shown that a tumor suppressor gene (CHD5) on chromosome 1p is in fact within a known CNV 50 . As such, it is conceivable that CNVs could contribute to the pathogenic phenotype observed in MDS.
Our finding of a high degree of genomic complexity and relatively few recurring alterations support the view that MDS represents a heterogenous disease manifested by the dysregulation of a large number of genes. The prognostic significance of a greater degree of genomic alteration suggests that DNA damage and aberrant DNA repair mechanisms may contribute to MDS, and potentially offer an ancillary test for diagnosis and prognosis of low-risk MDS patients.
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